Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
Фаза 2
Завершено
NCT03573024
| Заболевание | Acute Myeloid Leukemia |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | University of Colorado, Denver |
|---|
| Статус | Завершено |
|---|
| Участники | 36 участн. |
|---|
| Вмешательство | Azacitidine, Venetoclax |
|---|
| Дата начала | 28.11.2018 |
|---|
| Дата завершения | 14.04.2025 |
|---|
| Публикация результатов | 11.06.2026 |
|---|
Кратко
This study aims to treat non-elderly adult patients, who were previously untreated for acute myeloid leukemia, using venetoclax and azacitidine.
Response Rate, Measured by the European Leukemia Net Definition: (CRMRD-+CR+CRi+MLFS)
Study start date to study end date, or death, whichever comes first, approximately 4 years · Participants
| Azacitidine and Venetoclax | 25 Participants |
|---|
Number of Participants That Achieved Minimal Residual Disease (MRD) Negative Responses
Study start date to study end date, or death, whichever comes first, approximately 4 years · Participants
| Azacitidine and Venetoclax | 23 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.